Lido Advisors’s TG Therapeutics TGTX Stock Holding History

Lido Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.06M	Buy	19,305 +1,565	+9%	+$64K	﹤0.01%	1061
2026 Q1	$589K	Buy	17,740 +3,180	+22%	+$94.8K	﹤0.01%	1210
2025 Q4	$516K	Buy	14,560 +284	+2%	+$9.28K	﹤0.01%	1282
2025 Q3	$516K	Buy	14,276 +541	+4%	+$17.8K	﹤0.01%	1220
2025 Q2	$494K	Buy	13,735 +5,837	+74%	+$217K	﹤0.01%	1109
2025 Q1	$311K	Buy	7,898 +218	+3%	+$7.33K	﹤0.01%	1200
2024 Q4	$231K	Buy	+7,680	New	+$220K	﹤0.01%	1322
2021 Q4	–	Sell	-7,785	Closed	-$259K	–	1044
2021 Q3	$259K	Buy	7,785 +185	+2%	+$5.72K	﹤0.01%	800
2021 Q2	$295K	Hold	7,600	–	–	﹤0.01%	729
2021 Q1	$366K	Hold	7,600	–	–	0.01%	593
2020 Q4	$395K	Hold	7,600	–	–	0.01%	541
2020 Q3	$203K	Buy	+7,600	New	+$175K	0.01%	588

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Lido Advisors's TGTX Position: Q2 2026 in Review

Lido Advisors increased its TG Therapeutics (TGTX) stake by 8.8% in Q2 2026, buying an estimated $64K and bringing the position to 19,305 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1061.

Lido Advisors first reported a position in TGTX in Q3 2020 and has held it in 12 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Lido Advisors held 19,305 shares of TG Therapeutics worth $1.06M as of Q2 2026.
Lido Advisors bought 1,565 TG Therapeutics shares in Q2 2026, an estimated $64K.
TG Therapeutics made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #1061 holding.
Lido Advisors first reported a position in TG Therapeutics in Q3 2020 and has held it in 12 quarters since.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.